Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.43 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12245529 | 0.88 | CHRNB4 (0.47) | CHRNB4CHRNA3CRHR1LIPCLIPG | |
| SCHEMBL12205243 | 0.86 | CHRNB4 (0.48) | CHRNB4CHRNA3CRHR1PIM1FLT3 | |
| SCHEMBL12205372 | 0.85 | FLT3 (0.45) | CNR2KDRKCNH3CCNT1CDK9 | |
| SCHEMBL12205201 | 0.76 | TGFBR1 (0.56) | CRHR1 | |
| SCHEMBL1462718 | 0.72 | CCNT1 (0.47) | CNR2KDRKCNH3CCNT1CDK9 | |
| SCHEMBL12205218 | 0.72 | CCNT1 (0.47) | CNR2KDRKCNH3CCNT1CDK9 | |
| SCHEMBL12205225 | 0.71 | APP (0.51) | CRHR1PIM1FLT3ABL1BCR | |
| SCHEMBL1241605 | 0.70 | LIPC (0.46) | CNR2CRHR1LIPCLIPG | |
| SCHEMBL12247505 | 0.70 | CHRNB4 (0.46) | CHRNB4CHRNA3ABL1BCR | |
| SCHEMBL15717583 | 0.70 | PIM1 (0.55) | CNR2PIM1PIM2PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | AC IMMUNE, S.A. (CH) | 2011-10-20 | — | — | US | disclosed |
| EP-2377860-A1 | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC Immune S.A. (CH) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256064-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins | APP, PSEN1, PSEN2 | CNR2 1709/4885CHRNB4 193/4885CHRNA3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.